Age: 22.0
Sex: F
Vaccine: HPV9
Symptoms: Pulmonary mass, Seizure
Clinical narrative: pneumomediastinum; due to vax triggered return of seizures; eyes became infected; fatigues; bruising developed over 2/3rd of body/unexplained bruising; breathing issues; nodule on lung; immune system is being destroyed; blood clotting issue was nonexistent before this vaccine; DNA is being manipulated; This report was identified from a line listing obtained on request by the Company from the FDA under the Freedom of Information Act. The information was obtained from the patient, a 22-year old White female patient with epilepsy, post-traumatic stress disorder, anxiety, and allergy to penicillin, levetiracetam (KEPPRA), sulfadiazine (SULFA) and pregabalin (LYRICA).   As adverse event following any previous vaccine, the patient reported to have received infant diphtheria toxoid (+) pertussis vaccine (+) tetanus toxoid (DPT) and measles virus vaccine live (Enders-Edmonston) (+) mumps virus vaccine live (Jeryl Lynn) (+) rubella virus vaccine live (Wistar RA 27/3)) (MMR) vaccine as a child and developed vaccination injury described as sensory issues, loss ability to eat, loss speech at 3 year-old which required preschool teacher and was also referred to speech therapy. Concomitant therapies included multivitamins, diazepam (VALIUM) and ethinyl estradiol, ferrous fumarate, and norethindrone acetate (LO LOESTRIN FE).        On 01-FEB-2017 (also reported as February, 2017), in the morning, the patient received the first dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast)(GARDASIL 9), intramuscular (IM), in the left arm, for prophylaxis (dosage, lot # and expiration date were not provided). The patient was not given a copy of the vaccine insert product information or made aware of product concerns, safety or potential harm, no adverse reactions were discussed. At the vaccination time, she explained that she had a history of seizures and she was told that it was safe to receive this vaccine. She was asked to sign a document indicating her history of seizures, also, she had to fill out a risk form listing epilepsy and other seizure disorders, where she checked "Yes" to have.  Within hours of the injection, the patient's eyes became infected, she visited urgent care a few times, as antibiotic drops alone did not help. Also the patient was fatigued, bruising developed over 2/3rd of body, visited her primary care provider for blood work and was referred to hematology/oncology for additional blood work, testing for autoimmune disorder, lupus, etc. (results were not provided). Unexplained bruising/blood clotting issue was nonexistent before this vaccine and continued to increase and decrease. Due to vaccine, which triggered the return of seizures which had been absent for 2 years, bruising continued today to increase and decrease since the vaccinations. The patient also developed breathing issues and a nodule on lung (pneumomediastinum), and was admitted for treatment and observation.  On 20-MAR-2017, (also reported as 20 or 24-MAR-2017) the patient received the second dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast)(GARDASIL 9), intramuscular (IM), in the left arm, for prophylaxis (dosage, lot # and expiration date were not provided). The patient stated that she never went back for a third dose due to adverse disabling reactions. However, following the second dose, after being epileptic seizure free for 2 years, her seizures returned several weeks later in early May 2017. All future vaccines were refused, "and repeated harm was being noted from any and all vaccines". She affirmed, her immune system was destroyed, and deoxyribonucleic acid (DNA) was being manipulated.   According to the reporter, the events required a doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care, required hospitalization (2 days of stay) and were considered disabling or generated permanent damage. In addition, all the events were related to hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast)(GARDASIL 9).  At the reporting time, the patient had not recovered from any adverse event.  Follow-up information has been received from the healthcare provider's office on 22-OCT-2019.  They confirmed no reports to the office of any patient with adverse reactions; no symptoms and signs, unknown patients and unknown events.